Veru INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

17 Dec 2025

VERU

10-K: Veru Inc. 2025 10-K: Clinical Progress Amidst Financial Challenges

Veru Inc. reports significant clinical advancements for enobosarm and sabizabulin, alongside substantial net losses and a going concern warning, necessitating further capital.

NASDAQ

16 Dec 2024

VERU

Veru INC

10-K: Veru Inc. Reports Fiscal Year 2024 Results, Focuses on Enobosarm Development

Veru Inc. reports a net loss for fiscal year 2024 while advancing its enobosarm program for obesity and seeking external funding for sabizabulin.

NASDAQ

1 Apr 2024

VERU

Veru INC

10-K/A: Veru Inc. Restates Financials Due to R&D Expense Errors, Identifies Material Weakness

Veru Inc. has filed an amended annual report to restate its financial statements for fiscal years 2023 and 2022 due to errors in accounting for research and development expenses, also identifying a material weakness in internal controls.